查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
白介素 6 (IL-6) 抑制剂市场、份额、规模、趋势、行业分析报告：按药物类型；按疾病类型；按分销管道；按地区；细分市场预测，2023-2032 年
市场调查报告书
商品编码
1346913

白介素 6 (IL-6) 抑制剂市场、份额、规模、趋势、行业分析报告：按药物类型；按疾病类型；按分销管道；按地区；细分市场预测，2023-2032 年

Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，白细胞介素 6 (IL-6) 抑制剂的全球市场预计到 2032 年将达到 863.1 亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

白细胞介素 6 (IL-6) 抑制剂的日益普及促使公司和许多组织投资于研发。 例如，2022年12月，静脉注射（IV）托珠单抗（Actemra）被美国食品药物管理局（FDA）核准用于特殊情况下住院病患的COVID-19管理。 由于Roche的批准，托珠单抗是 FDA 批准的第一个用于治疗大流行病毒的单株抗体。 此外，2021年9月，Hetero的托珠单抗生物相似药获得了印度药品监管总局（DCGI）的上市批准，托珠单抗是一种用于住院患者的COVID-19治疗药物。 多个组织和行业参与者的贡献正在显着推动全球市场的成长。

自体免疫疾病和发炎性疾病的日益普及预计将刺激全球市场的发展。 IL-6在多种自体免疫和发炎疾病的发展中发挥重要作用，包括类风湿性关节炎、幼年特发性关节炎、Castleman疾病和细胞激素释放症候群(CRS)。 这些疾病在全球范围内的盛行率不断上升，推动了对 IL-6 抑制剂等有效治疗药物的需求。

慢性发炎性疾病盛行率的增加是推动全球市场成长的主要因素之一。 类风湿性关节炎、幼年特发性关节炎和卡斯尔曼氏症等慢性发炎性疾病在全世界不断增加。 例如，在北美和欧洲，估计每 10,000 名儿童中有 4 至 16 名患有幼年特发性关节炎。 IL-6 抑制剂已被证明可以有效控制这些疾病的症状和进展，从而推动了对 IL-6 抑制剂的需求。 为此，正在开发世界市场。

白细胞介素 6 (IL-6) 抑制剂市场报告重点

托珠单抗预计将在 2022 年创下最大的市场份额，因为它是首批获批并进入市场的 IL-6 抑制剂之一。

由于类风湿性关节炎的盛行率相对较高，预计将占全球市场最大的销售份额

专卖零售店是IL-6抑制剂的重要通路，2022年占全球销售额的最大份额

由于公司和组织临床试验的增加以及产业研发的激增，北美将在 2022 年占据最大份额。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球白血球介素 6 (IL-6) 抑制剂市场洞察

  • 白血球介素 6 (IL-6) 抑制剂市场 - 通路概况
  • 白介素6（IL-6）抑制剂的市场动态
    • 推动者和机会
      • 类风湿性关节炎 (RA) 盛行率不断上升
      • 热门白细胞介素 6 抑制剂
    • 抑制因素和挑战
      • 开发成本高
  • PESTEL 分析
  • 白介素 6 (IL-6) 抑制剂市场通路趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章依疾病类型划分的全球白血球介素 6 (IL-6) 抑制剂市场

  • 主要发现
  • 简介
  • 类风湿性关节炎
  • 卡斯尔曼病
  • 癌症（肾臟癌、摄护腺癌）
  • 动脉炎

第 6 章全球白血球介素 6 (IL-6) 抑制剂市场（以药物类型）

  • 主要发现
  • 简介
  • 托珠单抗
  • 司妥昔单抗
  • 西尔万特

第 7 章全球白血球介素 6 (IL-6) 抑制剂市场（依通路）

  • 主要发现
  • 简介
  • 零售药局
  • 医院药房
  • 专业药房
  • 网路药局
  • 其他销售管道

第 8 章全球白血球介素 6 (IL-6) 抑制剂市场（按地区）

  • 主要发现
  • 简介
    • 白细胞介素 6 (IL-6) 抑制剂市场评估，地区，2019-2032 年
  • 白细胞介素 6 (IL-6) 抑制剂市场 - 北美
    • 北美：白细胞介素 6 (IL-6) 抑制剂市场，依疾病类型划分，2019-2032 年
    • 北美：2019-2032 年白介素 6 (IL-6) 抑制剂市场（依分销管道）
    • 北美：2019-2032 年白介素 6 (IL-6) 抑制剂市场（依药物类型）
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 美国
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 加拿大
  • 白细胞介素 6 (IL-6) 抑制剂市场 - 欧洲
    • 欧洲：白细胞介素 6 (IL-6) 抑制剂市场，依疾病类型划分，2019-2032 年
    • 欧洲：白血球介素 6 (IL-6) 抑制剂市场（依通路），2019-2032 年
    • 欧洲：白细胞介素 6 (IL-6) 抑制剂市场（依药物类型），2019-2032 年
    • 白血球介素 6 (IL-6) 抑制剂市场 - 英国
    • 白血球介素 6 (IL-6) 抑制剂市场 - 法国
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 德国
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 义大利
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 西班牙
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 荷兰
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 俄罗斯
  • 白血球介素 6 (IL-6) 抑制剂市场 - 亚太地区
    • 亚太地区：白血球介素 6 (IL-6) 抑制剂市场（依疾病类型），2019-2032 年
    • 亚太地区：白血球介素 6 (IL-6) 抑制剂市场（依通路），2019-2032 年
    • 亚太地区：白血球介素 6 (IL-6) 抑制剂市场（依药物类型），2019-2032 年
    • 白血球介素 6 (IL-6) 抑制剂市场 - 中国
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 印度
    • 白血球介素 6 (IL-6) 抑制剂市场 - 马来西亚
    • 白血球介素 6 (IL-6) 抑制剂市场 - 日本
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 印尼
    • 白血球介素 6 (IL-6) 抑制剂市场 - 韩国
  • 白细胞介素 6 (IL-6) 抑制剂市场 - 中东和非洲
    • 中东和非洲：白细胞介素 6 (IL-6) 抑制剂市场（按疾病类型），2019-2032 年
    • 中东和非洲：白细胞介素 6 (IL-6) 抑制剂市场（按分销管道），2019-2032 年
    • 中东和非洲：白细胞介素 6 (IL-6) 抑制剂市场（按药物类型），2019-2032 年
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 沙乌地阿拉伯
    • 白血球介素 6 (IL-6) 抑制剂市场 - 阿拉伯联合大公国
    • 白血球介素 6 (IL-6) 抑制剂市场 - 以色列
    • 白血球介素 6 (IL-6) 抑制剂市场 – 南非
  • 白细胞介素 6 (IL-6) 抑制剂市场 - 拉丁美洲
    • 拉丁美洲：白细胞介素 6 (IL-6) 抑制剂市场，依疾病类型划分，2019-2032 年
    • 拉丁美洲：白细胞介素 6 (IL-6) 抑制剂市场，依分销管道划分，2019-2032 年
    • 拉丁美洲：白介素 6 (IL-6) 抑制剂市场（按药物类型），2019-2032 年
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 墨西哥
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 巴西
    • 白细胞介素 6 (IL-6) 抑制剂市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • AbbVie
  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson and Johnson Services
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche
  • Teva Pharmaceutical
Product Code: PM3720

The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032, according to a new study by Polaris Market Research. The report "Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing popularity of interleukin-6 (IL-6) inhibitors has led businesses and many organizations to invest in research and development. For example, in December 2022, Tocilizumab (Actemra), administered intravenously (IV), was authorized by the US Food and Drug Administration (FDA) for the management of COVID-19 in hospitalized individuals receiving extra care. Tocilizumab was the first monoclonal antibody approved by the FDA to treat the pandemic virus, thanks to the approval given to Roche. In addition to this, in September 2021, Hetero received approval from the Drug Controller General of India (DCGI) for the sale of a biosimilar version of Tocilizumab, a COVID-19 medication for hospitalized people. Contributions of several organizations and industry participants are significantly augmenting the market's growth worldwide.

The increasing prevalence of autoimmune and inflammatory diseases will likely spur the global market's development. IL-6 is critical in the pathogenesis of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome (CRS). The rising prevalence of these conditions worldwide drives the demand for effective therapies like IL-6 inhibitors.

The increasing prevalence of chronic inflammatory conditions is one of the primary factors likely to enhance the market's growth globally. Chronic inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease are rising globally. For example, as per the estimates, 4 to 16 out of every 10,000 kids in North America and Europe will have juvenile idiopathic arthritis. IL-6 inhibitors have shown efficacy in managing the symptoms and progression of these conditions, driving the demand for IL-6 inhibitors. Henceforth, this heightens the development in the global market.

Interleukin-6 (IL-6) Inhibitors Market Report Highlights

Tocilizumab drug is anticipated to record the largest market share in the year of 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market

Rheumatoid arthritis disease type is expected to garner the largest revenue in the global market due to relatively high prevalence of the diseases

Specialty retailers segment is accounting largest market share of the global revenue in the fiscal year of 2022 as these are a key distribution channel for IL-6 inhibitors

North America held the largest share as of 2022 due to increasing clinical trials among companies and organizations and surging research and development in the industry

The global players include: AbbVie, inc., AstraZeneca, Bausch Health, Johnson and Johnson Services, Novartis, GlaxoSmithKline, Eli Lilly, Teva Pharmaceutical, Regeneron Pharmaceuticals, Roche, and others

Polaris Market Research has segmented the Interleukin-6 (IL-6) Inhibitors market report based on drug type, disease type, and distribution channel, and region:

Interleukin-6 (IL-6) Inhibitors, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Tocilizumab
  • Siltuximab
  • Sylvant

Interleukin-6 (IL-6) Inhibitors, Disease Type Outlook (Revenue - USD Billion, 2019-2032)

  • Rheumatoid Arthritis
  • Castleman's disease
  • Cancers (Renal cancer, Prostate cancer)
  • Arteritis

Interleukin-6 (IL-6) Inhibitors, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

  • Retail Pharmacies
  • Hospital pharmacies
  • Specialty pharmacies
  • Online pharmacies
  • Other Sales Channel

Interleukin-6 (IL-6) Inhibitors, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Interleukin-6 (IL-6) Inhibitors Market Insights

  • 4.1. Interleukin-6 (IL-6) Inhibitors Market - Distribution Channel Snapshot
  • 4.2. Interleukin-6 (IL-6) Inhibitors Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of rheumatoid arthritis (RA)
      • 4.2.1.2. High popularity of interleukin-6 inhibitor
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High development cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Interleukin-6 (IL-6) Inhibitors Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Rheumatoid Arthritis
    • 5.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Rheumatoid Arthritis, by Region, 2019-2032 (USD Billion)
  • 5.4. Castleman's disease
    • 5.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Castleman's disease, by Region, 2019-2032 (USD Billion)
  • 5.5. Cancers (Renal cancer, Prostate cancer)
    • 5.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Cancers (Renal cancer, Prostate cancer), by Region, 2019-2032 (USD Billion)
  • 5.6. Arteritis
    • 5.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Arteritis, by Region, 2019-2032 (USD Billion)

6. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Tocilizumab
    • 6.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Tocilizumab, by Region, 2019-2032 (USD Billion)
  • 6.4. Siltuximab
    • 6.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Siltuximab, by Region, 2019-2032 (USD Billion)
  • 6.5. Sylvant
    • 6.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Sylvant, by Region, 2019-2032 (USD Billion)

7. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Retail Pharmacies
    • 7.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospital pharmacies
    • 7.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Hospital pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Specialty pharmacies
    • 7.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Specialty pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Online pharmacies
    • 7.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Online pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.7. Other sales channel
    • 7.7.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Other sales channel, By Region, 2019-2032 (USD Billion)

8. Global Interleukin-6 (IL-6) Inhibitors Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Interleukin-6 (IL-6) Inhibitors Market - North America
    • 8.3.1. North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Interleukin-6 (IL-6) Inhibitors Market - U.S.
      • 8.3.4.1. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Interleukin-6 (IL-6) Inhibitors Market - Canada
      • 8.3.5.1. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Interleukin-6 (IL-6) Inhibitors Market - Europe
    • 8.4.1. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Interleukin-6 (IL-6) Inhibitors Market - UK
      • 8.4.4.1. UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Interleukin-6 (IL-6) Inhibitors Market - France
      • 8.4.5.1. France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Interleukin-6 (IL-6) Inhibitors Market - Germany
      • 8.4.6.1. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Interleukin-6 (IL-6) Inhibitors Market - Italy
      • 8.4.7.1. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Interleukin-6 (IL-6) Inhibitors Market - Spain
      • 8.4.8.1. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Interleukin-6 (IL-6) Inhibitors Market - Netherlands
      • 8.4.9.1. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Interleukin-6 (IL-6) Inhibitors Market - Russia
      • 8.4.10.1. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Interleukin-6 (IL-6) Inhibitors Market - Asia Pacific
    • 8.5.1. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Interleukin-6 (IL-6) Inhibitors Market - China
      • 8.5.4.1. China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Interleukin-6 (IL-6) Inhibitors Market - India
      • 8.5.5.1. India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Interleukin-6 (IL-6) Inhibitors Market - Malaysia
      • 8.5.6.1. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Interleukin-6 (IL-6) Inhibitors Market - Japan
      • 8.5.7.1. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Interleukin-6 (IL-6) Inhibitors Market - Indonesia
      • 8.5.8.1. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Interleukin-6 (IL-6) Inhibitors Market - South Korea
      • 8.5.9.1. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Interleukin-6 (IL-6) Inhibitors Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Interleukin-6 (IL-6) Inhibitors Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Interleukin-6 (IL-6) Inhibitors Market - UAE
      • 8.6.5.1. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Interleukin-6 (IL-6) Inhibitors Market - Israel
      • 8.6.6.1. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Interleukin-6 (IL-6) Inhibitors Market - South Africa
      • 8.6.7.1. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Interleukin-6 (IL-6) Inhibitors Market - Latin America
    • 8.7.1. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Interleukin-6 (IL-6) Inhibitors Market - Mexico
      • 8.7.4.1. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Interleukin-6 (IL-6) Inhibitors Market - Brazil
      • 8.7.5.1. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Interleukin-6 (IL-6) Inhibitors Market - Argentina
      • 8.7.6.1. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bausch Health
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. GlaxoSmithKline
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson and Johnson Services
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Regeneron Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teva Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 2 Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 6 North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 18 UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 21 France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 42 China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 45 India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Interleukin-6 (IL-6) Inhibitors Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Disease Type
  • Figure 9. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Interleukin-6 (IL-6) Inhibitors Market